Tofacitinib Receives FDA Approval for Treatment of Ulcerative Colitis

Article

Tofacitinib is indicated for the treatment of adult patients with severely active ulcerative colitis, severely active rheumatoid arthritis (RA), or psoriatic arthritis (PsA).

The FDA has approved tofacitinib (Xeljaz XR, Pfizer, Inc) extended-release 11 mg and 22 mg tablets for the once-daily treatment of adult patients with moderately to severely active ulcerative colitis (UC) after an inadequate response or intolerance to TNF blockers.

“Ulcerative colitis is a chronic inflammatory disease of the colon that can significantly affect a patient’s quality of life and be emotionally burdensome due to symptoms, flares and complications,” said Michael Corbo, chief development officer of Inflammation & Immunology for Pfizer Global Product Development. “We are pleased to now offer patients with moderately to severely active ulcerative colitis and their health care providers a convenient once-daily dosing option with [tofactitinib].”

Tofacitinib is indicated for the treatment of adult patients with the following 3 indications:

  • Moderately to severely active UC for patients who have had an inadequate response to or who are intolerant to TNF blockers.
  • Moderately to severely active RA who have had an inadequate response or intolerance to methotrexate.
  • Active PsA, for patients who have had an inadequate response or intolerance to methotrexate or other disease-modifying antirheumatic drugs.

Tofacitinib 10 mg twice daily or tofacitinib 22 mg once daily may be given for 8 weeks or up to a maximum of 16 weeks as induction therapy. Following tofacitinib 5 mg twice daily, tofacitinib 11 mg once daily may be given as maintenance treatment.

Reference

FDA Approves XELJANZ XR (Tofacitinib) Extended-Release Tablets for the Treatment of Ulcerative Colitis [press release]. Pfizer website. Published December 12, 2019. https://www.pfizer.com/news/press-release/press-release-detail/fda_approves_xeljanz_xr_tofacitinib_extended_release_tablets_for_the_treatment_of_ulcerative_colitis. Accessed December 13, 2019.

Related Videos
Image Credit: SciePro - stock.adobe.com
Pharmacist selling medications in the pharmacy | Image Credit: rh2010 - stock.adobe.com
Atopic dermatitis on a patient's hand -- Image credit: Ольга Тернавская | stock.adobe.com
biosimilar word or concept represented by wooden letter tiles on a wooden table with glasses and a book | Image Credit: lexiconimages - stock.adobe.com
Image credit: alicja neumiler | stock.adobe.com
Laboratory test tubes and solution with stethoscope background | Image Credit: Shutter2U - stock.adobe.com
Laboratory test tubes and solution with stethoscope background | Image Credit: Shutter2U - stock.adobe.com
Image credit: Krakenimages.com | stock.adobe.com
Human brain digital illustration. Electrical activity, flashes, and lightning on a blue background. | Image Credit: Siarhei - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.